Soon after the start of the coronavirus disease 2019 (COVID-19) pandemic, in May 2020, more than 1300 trials were registered worldwide, 82% of which were devoted to assessing drugs or biologics [1]. Most of them were non-randomised trials or randomised controlled trials (RCTs). A few were adaptive, platform trials. However, in March 2020, the public hospitals of Paris (France) registered a cohort study, CORIMUNO-19 (NCT04324047), aiming to collect observational data to nest a series of RCTs to assess interventions for COVID-19 patients, i.e. a cohort multiple RCT (cmRCT). This clinical research approach has been exceptional in the COVID-19 pandemic.

2019 年冠状病毒病 (COVID-19) 大流行开始后不久，即 2020 年 5 月，全球注册了 1300 多项试验，其中 82% 用于评估药物或生物制剂 [1]。其中大多数是非随机试验或随机对照试验（RCT）。一些是自适应平台试验。然而，2020 年 3 月，巴黎（法国）的公立医院注册了一项队列研究 CORIMUNO-19（NCT04324047），旨在收集观察数据以嵌套一系列 RCT，以评估针对 COVID-19 患者的干预措施，即队列多个随机对照试验（cmRCT）。这种临床研究方法在 COVID-19 大流行中表现出色。